Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Inventiva
  6. News
  7. Summary
    IVA   FR0013233012

INVENTIVA

(IVA)
  Report
Real-time Euronext Paris  -  06:27 2022-11-29 am EST
4.480 EUR   +8.47%
11/28Inventiva Wins New US Patent For Liver Disease Drug
MT
11/28Inventiva secures a new patent expanding the IP protection of its lead product candidate lanifibranor in the US
GL
11/28Inventiva secures a new patent expanding the IP protection of its lead product candidate lanifibranor in the US
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

Inventiva S.A. Reports Earnings Results for the Half Year Ended June 30, 2022

09/22/2022 | 02:30am EST

Inventiva S.A. reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was EUR 0.067 million compared to EUR 0.139 million a year ago. Net loss was EUR 29.47 million compared to EUR 23.14 million a year ago.

Basic loss per share from continuing operations was EUR 0.72 compared to EUR 0.6 a year ago. Diluted loss per share from continuing operations was EUR 0.72 compared to EUR 0.6 a year ago.


© S&P Capital IQ 2022
All news about INVENTIVA
11/28Inventiva Wins New US Patent For Liver Disease Drug
MT
11/28Inventiva secures a new patent expanding the IP protection of its lead product candidat..
GL
11/28Inventiva secures a new patent expanding the IP protection of its lead product candidat..
AQ
11/21Inventiva announces a new Director of the Board of Directors
GL
11/21Inventiva announces a new Director of the Board of Directors
AQ
11/21Inventiva Announces Lucy Lu as the Director of its Board of Directors
CI
11/11Inventiva reports 2022 Third Quarter Financial Information
AQ
11/10Inventiva reports 2022 Third Quarter Financial Information¹
GL
11/10Inventiva reports 2022 Third Quarter Financial Information¹
AQ
11/07European ADRs Rise in Monday Trading
MT
More news
Analyst Recommendations on INVENTIVA
More recommendations
Financials
Sales 2022 11,8 M 12,3 M 12,3 M
Net income 2022 -61,3 M -63,7 M -63,7 M
Net Debt 2022 13,1 M 13,6 M 13,6 M
P/E ratio 2022 -2,68x
Yield 2022 -
Capitalization 174 M 181 M 181 M
EV / Sales 2022 15,8x
EV / Sales 2023 72,5x
Nbr of Employees 109
Free-Float 74,9%
Chart INVENTIVA
Duration : Period :
Inventiva Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INVENTIVA
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 4,13 €
Average target price 17,62 €
Spread / Average Target 327%
EPS Revisions
Managers and Directors
Frédéric Cren Chairman & Chief Executive Officer
Jean Volatier Chief Financial & Administrative Officer
Pierre Broqua Director, Chief Scientific Officer & Deputy CEO
Michael P. Cooreman Chief Medical Officer
Alice Roudot-Ketelers Vice President-Clinical Operations
Sector and Competitors
1st jan.Capi. (M$)
INVENTIVA-64.82%181
VERTEX PHARMACEUTICALS43.58%80 935
REGENERON PHARMACEUTICALS, INC.16.58%79 191
BIONTECH SE-37.36%39 245
WUXI APPTEC CO., LTD.-35.85%30 708
GENMAB A/S22.93%29 471